Clinical utility of measurement of anti-müllerian hormone in reproductive endocrinology

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 12, 2010, Pages 5144-5154

  Ledger, William L ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CLOMIFENE CITRATE; ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; INHIBIN B; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; RECOMBINANT FOLLITROPIN;

CANCER CHEMOTHERAPY; EARLY MENOPAUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE FERTILITY; FERTILIZATION IN VITRO; GRANULOSA CELL; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; IMMUNOHISTOCHEMISTRY; MENOPAUSE; MENSTRUAL CYCLE; OVARIAN RESERVE; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SUPEROVULATION;

EID: 78650045807     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0701     Document Type: Review

References (110)

1. Picard JY, Belville C 2002 Genetics and molecular pathology of anti-Mullerian hormone and its receptor. J Soc Biol 196:217-221
2. Cohen-Haguenauer O, Picard JY, Mattéi MG, Serero S, Nguyen VC, de Tand MF, Guerrier D, Hors-Cayla MC, Josso N, Frézal J 1987 Mapping of the gene for anti-müllerian hormone to the short arm of human chromosome 19. Cytogenet Cell Genet 44:2-6 (Pubitemid 17037164)
3. Deffieux X, Antoine JM 2003 [Inhibins, activins and anti-Müllerian hormone: structure, signalling pathways, roles and predictive value in reproductive medicine.] Gynecol Obstet Fertil 31:900-911
4. Münsterberg A, Lovell-Badge R 1991 Expression of the mouse anti-Müllerian hormone gene suggests a role in both male and female sexual differentiation. Development 113:613-624
5. Behringer RR, Finegold MJ, Cate RL 1994 Müllerian-inhibiting substance function during mammalian sexual development. Cell 79:415-425 (Pubitemid 124000768)
6. Lee MM, Donahoe PK 1993 Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocr Rev 14:152-164
7. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, Hasegawa Y, Noto RA, Schoenfeld D, MacLaughlin DT 1996 Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 81:571-576
8. Crisosto N, Codner E, Maliqueo M, Echiburú B, Sánchez F, Cassorla F, Sir-Petermann T 2007 Anti-Müllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 92:2739-2743 (Pubitemid 47037384)
9. La Marca A, De Leo V, Giulini S, Orvieto R, Malmusi S, Giannella L, Volpe A 2005 Anti-mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause. J Soc Gynecol Investig 12:545-548
10. Wang J, Dicken C, Lustbader JW, Tortoriello DV 2009 Evidence for a Müllerian-inhibiting substance autocrine/paracrine system in adult human endometrium. Fertil Steril 91:1195-1203
11. Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK 2003 Mullerian inhibiting substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci USA 100:15601-15606
12. Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK 2005 Endometrial cancer is a receptor-mediated target for Mullerian inhibiting substance. Proc Natl Acad Sci USA 102:111-116 (Pubitemid 40094437)
13. Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller Jr AF, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK 1999 Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res 5:3488-3499
14. Segev DL, Ha TU, Tran TT, Kenneally M, Harkin P, Jung M, MacLaughlin DT, Donahoe PK, Maheswaran S 2000 Mullerian inhibiting substance inhibits breast cancer cell growth through an NFκB-mediated pathway. J Biol Chem 275:28371-28379
15. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BC, Themmen AP 2004 Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 10:77-83
16. Hirobe S, He WW, Gustafson ML, MacLaughlin DT, Donahoe PK 1994 Müllerian inhibiting substance gene expression in the cycling rat ovary correlates with recruited or graafian follicle selection. Biol Reprod 50:1238-1243 (Pubitemid 24155462)
17. Gougeon A 1998 Ovarian follicular growth in humans: ovarian ageing and population of growing follicles. Maturitas 30:137-142
18. Knight PG, Glister C 2006 TGF-β superfamily members and ovarian follicle development. Reproduction 132:191-206
19. Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA, Themmen AP 1999 Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology 140:5789-5796
20. Cook CL, Siow Y, Taylor S, Fallat ME 2000 Serum Mullerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril 73:859-861
21. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ 2006 Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 91:4057-4063
22. La Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P, Volpe A 2004 Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 19:2738-2741 (Pubitemid 40028941)
23. Fanchin R, Schonäuer LM, Righini C, Guibourdenche J, Frydman R, Taieb J 2003 Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 18:323-327 (Pubitemid 36236265)
24. Sowers M, McConnell D, Gast K, Zheng H, Nan B, McCarthy JD, Randolph JF 7 December 2009 Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril 10.1016/j.fertnstert.2009.07.1674
25. Wunder DM, Bersinger NA, Yared M, Kretschmer R, Birkhäuser MH 2008 Statistically significant changes of antimüllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil Steril 89:927-933 (Pubitemid 351491234)
26. Baird DT 1987 A model for follicular selection and ovulation: lessons from superovulation. J Steroid Biochem 27:15-23
27. Arbo E, Vetori DV, Jimenez MF, Freitas FM, Lemos N, Cunha- Filho JS 2007 Serum anti-mullerian hormone levels and follicular cohort characteristics after pituitary suppression in the late luteal phase with oral contraceptive pills. Hum Reprod 22:3192-3196 (Pubitemid 351696766)
28. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D 2008 Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril 90:395-400
29. La Marca A, Giulini S, Orvieto R, De Leo V, Volpe A 2005 Anti- Müllerian hormone concentrations in maternal serum during pregnancy. Hum Reprod 20:1569-1572 (Pubitemid 40852249)
30. Nelson SM, Stewart F, Fleming R, Freeman DJ 2010 Longitudinal assessment of antimüllerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin. Fertil Steril 93:1356-1358
31. Mohamed KA, Davies WA, Lashen H 2006 Antimüllerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertil Steril 86:1515-1517
32. Eppig JJ 2001 Oocyte control of ovarian follicular development and function in mammals. Reproduction 122:829-838
33. Peters H 1979 Some aspects of early follicular development. In: Midgley AR, Sadler WA, eds. Ovarian follicular development and function. New York: Raven Press; 1-15
34. Macklon NS, Fauser BC 2005 Ovarian reserve. Semin Reprod Med 23:248-256
35. Richardson SJ, Senikas V, Nelson JF 1987 Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab 65:1231-1237
36. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF 1992 Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod 7:1342-1346
37. van Noord PA, Dubas JS, Dorland M, Boersma H, te Velde E 1997 Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors. Fertil Steril 68:95-102
38. Cramer DW, Xu H, Harlow BL 1995 Family history as a predictor of early menopause. Fertil Steril 64:740-745
39. Waylen AL, Metwally M, Jones GL, Wilkinson AJ, Ledger WL 2009 Effects of cigarette smoking upon clinical outcomes of assisted reproduction: a meta-analysis. Hum Reprod Update 15:31-44
40. Pigny P, Jonard S, Robert Y, Dewailly D 2006 Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 91: 941-945 (Pubitemid 43357762)
41. La Marca A, Pati M, Orvieto R, Stabile G, Carducci Artenisio A, Volpe A 2006 Serum anti-müllerian hormone levels in women with secondary amenorrhea. Fertil Steril 85:1547-1549
42. Knauff EA, Eijkemans MJ, Lambalk CB, ten Kate-Booij MJ, Hoek A, Beerendonk CC, Laven JS, Goverde AJ, Broekmans FJ, Themmen AP, de Jong FH, Fauser BC; Dutch Premature Ovarian Failure Consortium 2009 Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab [Erratum (2010) 95:465] 94:786-792
43. Partridge AH, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M, Ginsburg E 2010 Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 94:638-644
44. Taieb J, Belville C, Coussieu C, Guibourdenche J, Picard JY, Di clemente N 2008 [Two immunoassays for antimullerian hormone measurement: analytical and clinical performances.] Ann Biol Clin (Paris) 66:537-547
45. Streuli I, Fraisse T, Chapron C, Bijaoui G, Bischof P, de Ziegler D 2009 Clinical uses of anti-Müllerian hormone assays: pitfalls and promises. Fertil Steril 91:226-230
46. Lass A 2001 Assessment of ovarian reserve - is there a role for ovarian biopsy? Hum Reprod 16:1055-1057
47. Guthrie JR, Dennerstein L, Taffe JR, Lehert P, Burger HG 2004 The menopausal transition: a 9-year prospective population-based study. The Melbourne Women's Midlife Health Project. Climacteric 7:375-389
48. Mulders AG, Laven JS, Eijkemans MJ, de Jong FH, Themmen AP, Fauser BC 2004 Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod 19:2036-2042
49. Ranieri DM, Quinn F, Makhlouf A, Khadum I, Ghutmi W, McGarrigle H, Davies M, Serhal P 1998 Simultaneous evaluation of basal follicle-stimulating hormone and 17 β-estradiol response to gonadotropin-releasing hormone analogue stimulation: an improved predictor of ovarian reserve. Fertil Steril 70:227-233 (Pubitemid 28361472)
50. McIlveen M, Skull JD, Ledger WL 2007 Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod 22:778-785
51. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB 2006 A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 12:685-718 (Pubitemid 44605509)
52. Webber LJ, Stubbs SA, Stark J, Margara RA, Trew GH, Lavery SA, Hardy K, Franks S 2007 Prolonged survival in culture of preantral follicles from polycystic ovaries. J Clin Endocrinol Metab 92:1975-1978
53. Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, Mason H 2007 Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 92:240-245
54. Das M, Gillott DJ, Saridogan E, Djahanbakhch O 2008 Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. Hum Reprod 23:2122-2126
55. Carlsen SM, Vanky E, Fleming R 2009 Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum Reprod 24:1732-1738
56. Nardo LG, Yates AP, Roberts SA, Pemberton P, Laing I 2009 The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod 24:2917-2923
57. Georgopoulos NA, Saltamavros AD, Decavalas G, Piouka A, Katsikis I, Panidis D 2010 Serum AMH, FSH, and LH levels in PCOS. Fertil Steril 93:e13; author reply e14
58. Hart R, Doherty DA, Norman RJ, Franks S, Dickinson JE, Hickey M, Sloboda DM 8 January 2010 Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril doi: 10.1016/j.fertnstert.2009.11.002
59. Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ, Brinkworth GD 2009 The effect of weight loss on anti-Müllerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod 24:1976-1981
60. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D 2009 Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 296: E238-E243
61. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41-47
62. El-Halawaty S, Rizk A, Kamal M, Aboulhassan M, Al-Sawah H, Noah O, Al-Inany H 2007 Clinical significance of serum concentration of anti-Müllerian hormone in obese women with polycystic ovary syndrome. Reprod Biomed Online 15:495-499
63. Amer SA, Li TC, Ledger WL 2009 The value of measuring anti- Mullerian hormone in women with anovulatory polycystic ovary syndrome undergoing laparoscopic ovarian diathermy. Hum Reprod 24:2760-2766
64. Lie Fong S, Baart EB, Martini E, Schipper I, Visser JA, Themmen AP, de Jong FH, Fauser BJ, Laven JS 2008 Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality? Reprod Biomed Online 16:664-670
65. Nastri CO, Ferriani RA, Rocha IA, Martins WP 2010 Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet 27:121-128
66. Templeton A, Morris JK, Parslow W 1996 Factors that affect outcome of in-vitro fertilisation treatment. Lancet 348:1402-1406
67. Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC 2006 A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update 12:13-21
68. van der Gaast MH, Eijkemans MJ, van der Net JB, de Boer EJ, Burger CW, van Leeuwen FE, Fauser BC, Macklon NS 2006 Optimum number of oocytes for a successful first IVF treatment cycle. Reprod Biomed Online 13:476-480
69. Mathur R, Kailasam C, Jenkins J 2007 Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome. Hum Fertil Camb 10:75-85 (Pubitemid 46964274)
70. Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, Devroey P 2005 Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod 20:636-641 (Pubitemid 40425488)
71. Luke B, Brown MB, Morbeck DE, Hudson SB, Coddington 3rd CC, Stern JE; a SART Writing Group 9 July 2009 Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome. Fertil Steril doi: 10.1016/j.fertnstert.2009.05.092
72. Delvigne A, Rozenberg S 2003 Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 9:77-96
73. Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, Yang YS, Lee MS 2008 Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 23:160-167
74. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, Volpe A 2007 Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 22:766-771
75. Nelson SM, Yates RW, Fleming R 2007 Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Hum Reprod 22:2414-2421
76. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, Mitchell P, Ambrose P, Fleming R 2009 Anti-Müllerian hormone- based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 24:867-875
77. Cooper AR, Baker VL, Sterling EW, Ryan ME, Woodruff TK, Nelson LM 26 February 2010 The time is now for a new approach to primary ovarian insufficiency. Fertil Steril doi: 10.1016/j.fertnstert.2010.01.016
78. Nikolaou D, Templeton A 2004 Early ovarian ageing. Eur J Obstet Gynecol Reprod Biol 113:126-133
79. Miao YL, Kikuchi K, Sun QY, Schatten H 2009 Oocyte aging: cellular and molecular changes, developmental potential and reversal possibility. Hum Reprod Update 15:573-585
80. Devroey P, Fauser BC, Diedrich K; Evian Annual Reproduction (EVAR) Workshop Group 2009 Approaches to improve the diagnosis and management of infertility. Hum Reprod Update 15:391-408
81. Haadsma ML, Mooij TM, Groen H, Burger CW, Lambalk CB, Broekmans FJ, van Leeuwen FE, Bouman K, Hoek A; OMEGA Project Group 2010 A reduced size of the ovarian follicle pool is associated with an increased risk of a trisomic pregnancy in IVF-treated women. Hum Reprod 25:552-558
82. Haadsma ML, Groen H, Mooij TM, Burger CW, Broekmans FJ, Lambalk CB, Leeuwen FE, Hoek A; on behalf of The OMEGA Project Group 2010 Miscarriage risk for IVF pregnancies in poor responders to ovarian hyperstimulation. Reprod Biomed Online 20:191-200
83. de Boer EJ, den Tonkelaar I, te Velde ER, Burger CW, van Leeuwen FE; OMEGA Project Group 2003 Increased risk of early menopausal transition and natural menopause after poor response at first IVF treatment. Hum Reprod 18:1544-1552
84. Nikolaou D, Templeton A 2003 Early ovarian ageing: a hypothesis. Detection and clinical relevance. Hum Reprod 18:1137-1139
85. Wallace WH, Kelsey TW 2010 Human ovarian reserve from conception to the menopause. PLoS One 5:e8772
86. Broekmans FJ, Soules MR, Fauser BC 2009 Ovarian aging: mechanisms and clinical consequences. Endocr Rev 30:465-493
87. Nikolaou D 2008 How old are your eggs? Curr Opin Obstet Gynecol 20:540-544
88. Nardo LG, Gelbaya TA, Wilkinson H, Roberts SA, Yates A, Pemberton P, Laing I 2009 Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 92:1586-1593
89. Jayaprakasan K, Deb S, Batcha M, Hopkisson J, Johnson I, Campbell B, Raine-Fenning N 19 November 2009 The cohort of antral follicles measuring 2-6 mm reflects the quantitative status of ovarian reserve as assessed by serum levels of anti-Müllerian hormone and response to controlled ovarian stimulation. Fertil Steril doi: 10.1016/j.fertnstert.2009.10.022
90. Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine- Fenning N 2010 A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril 93:855-864
91. Broer SL, Mol BW, Hendriks D, Broekmans FJ 2009 The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 91:705-714
92. van Disseldorp J, Lambalk CB, Kwee J, Looman CW, Eijkemans MJ, Fauser BC, Broekmans FJ 2010 Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod 25:221-227
93. Check JH 2006 Pharmacological options in resistant ovary syndrome and premature ovarian failure. Clin Exp Obstet Gynecol 33:71-77
94. Hansen KR, Hodnett GM, Knowlton N, Craig LB 14 June 2010 Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril 10.1016/j.fertnstert.2010.04.006
95. van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, Fauser BJ, Themmen AP, te Velde ER 2005 Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 83:979-987 (Pubitemid 40501577)
96. Dondorp WJ, De Wert GM 2009 Fertility preservation for healthy women: ethical aspects. Hum Reprod 24:1779-1785
97. Tao T, Del Valle A 2008 Human oocyte and ovarian tissue cryo-preservation and its application. J Assist Reprod Genet 25:287-296
98. Practice Committee of the American Society for Reproductive Medicine; Practice Committee of the Society for Assisted Reproductive Technology 2006 Ovarian tissue and oocyte cryopreservation. Fertil Steril 86(5 Suppl 1):S142-S147
99. Skinner R, Wallace WH, Levitt GA; UK Children's Cancer Study Group Late Effects Group 2006 Long-term follow-up of people who have survived cancer during childhood. Lancet Oncol 7:489-498
100. Armstrong GT, Pan Z, Ness KK, Srivastava D, Robison LL 2010 Temporal trends in cause-specific late mortality among 5-year survivors of childhood cancer. J Clin Oncol 28:1224-1231
101. Sklar C 2005 Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr 34:25-27
102. Hickey M, Peate M, Saunders CM, Friedlander M 2009 Breast cancer in young women and its impact on reproductive function. Hum Reprod Update 15:323-339
103. Walshe JM, Denduluri N, Swain SM 2006 Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24:5769-5779
104. Anchan RM, Ginsburg ES 2010 Fertility concerns and preservation in younger women with breast cancer. Crit Rev Oncol Hematol 74:175-192
105. Knopman JM, Papadopoulos EB, Grifo JA, Fino ME, Noyes N 2010 Surviving childhood and reproductive-age malignancy: effects on fertility and future parenthood. Lancet Oncol 11:490-498
106. Bath LE, Wallace WH, Critchley HO 2002 Late effects of the treatment of childhood cancer on the female reproductive system and the potential for fertility preservation. BJOG 109:107-114
107. Ledger W, Wiebinga C, Anderson P, Irwin D, Holman A, Lloyd A 2009 Costs and outcomes associated with IVF using recombinant FSH. Reprod Biomed Online 19:337-342
108. Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA 2006 The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21:2583-2592
109. Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L 2007 Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 12:141-147
110. Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA 2003 Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Müllerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 18:2368-2374